Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.59
TEAR's Cash-to-Debt is ranked lower than
72% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.86 vs. TEAR: 0.59 )
Ranked among companies with meaningful Cash-to-Debt only.
TEAR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: No Debt Max: No Debt
Current: 0.59
Equity-to-Asset -0.22
TEAR's Equity-to-Asset is ranked lower than
95% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. TEAR: -0.22 )
Ranked among companies with meaningful Equity-to-Asset only.
TEAR' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.59  Med: 0.68 Max: 0.96
Current: -0.22
-1.59
0.96
Piotroski F-Score: 5
Altman Z-Score: -26.87
Beneish M-Score: -4.34
WACC vs ROIC
16.69%
-239.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -57.04
TEAR's Operating Margin % is ranked lower than
70% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. TEAR: -57.04 )
Ranked among companies with meaningful Operating Margin % only.
TEAR' s Operating Margin % Range Over the Past 10 Years
Min: -46452.17  Med: -341.61 Max: -57.03
Current: -57.04
-46452.17
-57.03
Net Margin % -71.11
TEAR's Net Margin % is ranked lower than
72% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. TEAR: -71.11 )
Ranked among companies with meaningful Net Margin % only.
TEAR' s Net Margin % Range Over the Past 10 Years
Min: -75902.17  Med: -403.82 Max: -71.11
Current: -71.11
-75902.17
-71.11
ROA % -71.95
TEAR's ROA % is ranked lower than
79% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. TEAR: -71.95 )
Ranked among companies with meaningful ROA % only.
TEAR' s ROA % Range Over the Past 10 Years
Min: -132.11  Med: -75.36 Max: -37.9
Current: -71.95
-132.11
-37.9
ROC (Joel Greenblatt) % -270.01
TEAR's ROC (Joel Greenblatt) % is ranked lower than
68% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. TEAR: -270.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TEAR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7452.46  Med: -3369.34 Max: -270.01
Current: -270.01
-7452.46
-270.01
3-Year Revenue Growth Rate 133.00
TEAR's 3-Year Revenue Growth Rate is ranked higher than
98% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. TEAR: 133.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TEAR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 20.5 Max: 263.5
Current: 133
0
263.5
3-Year EBITDA Growth Rate 72.80
TEAR's 3-Year EBITDA Growth Rate is ranked higher than
98% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. TEAR: 72.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TEAR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -77.7  Med: 13.9 Max: 169.6
Current: 72.8
-77.7
169.6
3-Year EPS without NRI Growth Rate 65.90
TEAR's 3-Year EPS without NRI Growth Rate is ranked higher than
96% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. TEAR: 65.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TEAR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -78.6  Med: 20 Max: 135.5
Current: 65.9
-78.6
135.5
GuruFocus has detected 2 Warning Signs with TearLab Corp $TEAR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TEAR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

TEAR Guru Trades in Q1 2016

Chuck Royce 85,000 sh (unchged)
» More
Q2 2016

TEAR Guru Trades in Q2 2016

Chuck Royce 85,000 sh (unchged)
» More
Q3 2016

TEAR Guru Trades in Q3 2016

Jim Simons 19,800 sh (New)
Chuck Royce 85,000 sh (unchged)
» More
Q4 2016

TEAR Guru Trades in Q4 2016

Jim Simons 38,100 sh (+92.42%)
Chuck Royce 85,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with TEAR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NAS:BASI, NYSE:BIO » details
Traded in other countries:TLB.Canada, OCVN.Germany,
TearLab Corp is an in-vitro diagnostic company. The Company commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film.

TearLab Corp was incorporated as OccuLogix, Inc. in Delaware in 2002. The Company is an in-vitro diagnostic company based in San Diego, California. The commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease, or DED. The Company's wholly-owned subsidiary, TearLab Research, Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company's business. The Company's first product, the TearLab Osmolarity System, enables the rapid measurement of tear osmolarity in the doctor's office. Osmolarity is a quantitative and specific biomarker that has been shown to assist in the diagnosis and disease management of DED. The innovation of the TearLab Osmolarity System is its ability to precisely and rapidly measure osmolarity in nanoliter volumes of tear samples, using an efficient and novel tear collection system at the point of care. The TearLab Osmolarity System consists of the following three components: the TearLab disposable, which is a single-use microfluidic microchip; the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator. The Company relies on two suppliers based in the United States for the manufacture of the Readers and Pens which are key components of the TearLab Osmolarity System. The Company also relies on a single supplier, MiniFAB (Aust) Pty Ltd. located in Australia, for the manufacture of the test cards which is also a key component of the TearLab Osmolarity System.

Ratios

vs
industry
vs
history
PS Ratio 0.14
TEAR's PS Ratio is ranked higher than
99% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. TEAR: 0.14 )
Ranked among companies with meaningful PS Ratio only.
TEAR' s PS Ratio Range Over the Past 10 Years
Min: 0.14  Med: 18.17 Max: 502.01
Current: 0.14
0.14
502.01
Current Ratio 3.76
TEAR's Current Ratio is ranked higher than
68% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. TEAR: 3.76 )
Ranked among companies with meaningful Current Ratio only.
TEAR' s Current Ratio Range Over the Past 10 Years
Min: 0.28  Med: 2 Max: 16.25
Current: 3.76
0.28
16.25
Quick Ratio 3.22
TEAR's Quick Ratio is ranked higher than
67% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. TEAR: 3.22 )
Ranked among companies with meaningful Quick Ratio only.
TEAR' s Quick Ratio Range Over the Past 10 Years
Min: 0.22  Med: 1.8 Max: 15.2
Current: 3.22
0.22
15.2
Days Inventory 103.81
TEAR's Days Inventory is ranked lower than
63% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.88 vs. TEAR: 103.81 )
Ranked among companies with meaningful Days Inventory only.
TEAR' s Days Inventory Range Over the Past 10 Years
Min: 61.57  Med: 135.98 Max: 219.56
Current: 103.81
61.57
219.56
Days Sales Outstanding 29.69
TEAR's Days Sales Outstanding is ranked higher than
88% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.18 vs. TEAR: 29.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEAR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.69  Med: 62.63 Max: 1487.77
Current: 29.69
29.69
1487.77
Days Payable 55.05
TEAR's Days Payable is ranked lower than
51% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. TEAR: 55.05 )
Ranked among companies with meaningful Days Payable only.
TEAR' s Days Payable Range Over the Past 10 Years
Min: 28.27  Med: 115.69 Max: 705.37
Current: 55.05
28.27
705.37

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.20
TEAR's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. TEAR: -17.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEAR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -132.1  Med: -42.6 Max: -5.6
Current: -17.2
-132.1
-5.6

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.01
TEAR's Price-to-Median-PS-Value is ranked higher than
99% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. TEAR: 0.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TEAR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.99 Max: 21.69
Current: 0.01
0.01
21.69
Earnings Yield (Greenblatt) % -61.35
TEAR's Earnings Yield (Greenblatt) % is ranked lower than
92% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.78 vs. TEAR: -61.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TEAR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -122.61  Med: 0 Max: 0
Current: -61.35
-122.61
0

More Statistics

Revenue (TTM) (Mil) $28.01
EPS (TTM) $ -43.20
Beta2.15
Short Percentage of Float0.73%
52-Week Range $2.80 - 9.10
Shares Outstanding (Mil)5.36

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -2.65
EPS without NRI ($) -2.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TEAR

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
TearLab Corp. :TEAR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
TEARLAB CORP Financials Mar 16 2017
TearLab Corp. :TEAR-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
TEARLAB CORP Files SEC form 10-K, Annual Report Mar 10 2017
TearLab reports 4Q loss Mar 09 2017
TearLab reports 4Q loss Mar 09 2017
TEARLAB CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 09 2017
TearLab Corporation Reports Fourth Quarter and Year End 2016 Financial Results Mar 09 2017
Q4 2016 TearLab Corp Earnings Release - After Market Close Mar 09 2017
TearLab Announces CE Marking for Next-Generation System Mar 06 2017
TEARLAB CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to... Feb 27 2017
TearLab Announces 1-for-10 Reverse Split of Common Stock Feb 24 2017
TearLab Corporation to Report Fourth Quarter and Full-year 2016 Financial Results on March 9, 2017 Feb 21 2017
TearLab Provides Update on International Market Milestones Feb 13 2017
TearLab Osmolarity System Receives Mexican Regulatory Approval Jan 25 2017
ETFs with exposure to TearLab Corp. : December 9, 2016 Dec 09 2016
TearLab Granted Extension by Nasdaq Nov 16 2016
TEARLAB CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Nov 14 2016
ETF’s with exposure to TearLab Corp. : November 10, 2016 Nov 10 2016
TEARLAB CORP Files SEC form 10-Q, Quarterly Report Nov 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)